DDX53 and neoplasm: Next, we treated CT26-Nanog tumor–bearing mice with intravenously administered chitosan nanoparticles carrying Mcl1- or GFP-targeting siRNA along with anti–PD-1, as illustrated in Supplemental Figure 14.